Given that JMJD3 is involved in a variety of normal physiological processes and prevents renal fibrosis and renal dysfunction, complete inhibition of JMJD3 may have off-target side effects when JMJD3 is used for therapeutic targeting in patients, especially those with CKD. This evidence concerns the gene KDM6B and chronic kidney disease.